Plain-English translation of NCT06758037 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a new treatment called HiR+X can help older adults with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) who are unable to tolerate standard chemotherapy. The treatment combines two medications (Zebtorizumab and Lenalidomide) with an additional targeted drug that is chosen based on genetic testing of your cancer. The goal is to see if this personalized approach can shrink tumors and help you feel better while being safer for your body than traditional chemotherapy.
Many older adults with this blood cancer cannot tolerate the harsh side effects of standard chemotherapy, leaving them with few treatment options. Researchers are testing whether this newer combination of gentler medications—guided by genetic information about your specific cancer—might work just as well or better while being easier for your body to handle.
You likely qualify if…
You likely don't qualify if…
You will receive the medication combination over seven treatment cycles (each cycle lasts several weeks). On your first day, you'll have genetic testing done on a sample of your cancer tissue and your blood to help determine which specific medication you should receive in your remaining six cycles. Then, depending on those test results, you will receive the personalized treatment plan. You will have regular visits to the hospital or clinic to receive the medications, have blood tests, and be monitored for side effects.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
First Affiliated Hospital of Ningbo University
Enrollment target
~50 participants
Started
January 2025
Primary completion
December 2026
Age range
70 Years – 100 Years
Last updated on clinicaltrials.gov in March 2025.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.